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Abstract 
 
 
Objective: The objective of this selective EBM review is to determine whether or not melatonin 
is an effective treatment for sleep problems in Autism. 
 
Study Design: Review of three English language, randomized controlled blinded trials published 
within peer-reviewed journals from 2006-2010 evaluating the efficacy of Melatonin as an oral 
sleep supplement in diagnosed autistic children. 
 
Data Sources: A double blind, randomized, placebo-controlled, crossover trial; a randomized 
controlled crossover trial; and a randomized controlled trial found using Cochrane, PubMed, and 
DynaMed. 
 
Outcomes Measured: Total night’s sleep duration, number of awakenings, and sleep latency time 
were all measured using both sleep diaries, completed by the parents or caregivers, as well as 
Actiwatch, a device worn to measure the activity of a participant. Common side effects of 
Melatonin were measured using a Side Effects Questionnaire (SEQ). 
 
Results: Wirojanan et al. 2008 reported night sleep duration was longer on Melatonin than 
placebo by 21 minutes (p=0.02). Wright et al. 2010 reported a significant difference between 
Melatonin and placebo in total sleep by an average of 52.3 minutes (p=0.002). Garstang et al. 
2006 reported an increase from 8.05h to 9.84h total sleep duration. 
 
Wirojanan et al. 2008 and Wright et al. 2010 reported no significant difference in number of 
night awakenings. Garstang et al. 2006 reported a difference between 0.35 baseline to 0.08 with 
Melatonin. 
 
Wirojanan et al. 2008 reported a mean sleep-onset latency shorter by 28 minutes (p=0.0001).  
Wright et al. 2010 reported an improvement of sleep latency by an average of 47 min  (p=0.004). 
Garstang et al. 2006 reported a difference in sleep latency from 2.6h baseline to 1.06h with use 
of Melatonin. Wright et al. 2010 reported no significant side effects in the SEQ. 
 
Conclusion: The results of the three studies presented evidence that the use of Melatonin to 
improve sleep problems in children with Autism is a safe and effective treatment option. While 
there is no significant improvement in the number of times a child awakens during the night, 
there is statistical significance to show using Melatonin improves sleep latency and total night’s 
sleep. 
 
Key Words:  Autism and Melatonin 	  	  	  	  	  	  
Introduction 
 The National Institute of Neurological Disorders and Stroke defines autism by a range of 
complex neurodevelopment disorders, characterized by social impairments, communication 
difficulties, and restricted, repetitive, and stereotyped patterns of behavior1. There are different 
types of autism that all fall within what clinicians call a spectrum, thus the term Autism 
Spectrum Disorder (ASD). The spectrum ranges from classical ASD, the most severe form, to 
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).  
 The incidence of autism has been increasing rapidly over the past decade. The CDC’s 
Autism and Developmental Disabilities Monitoring Network (ADDM) estimates about 1 in 88 
children have been identified with ASD2. While there is no difference in race, ethnic, and 
socioeconomic groups there is a predilection for sex. ASD is five times more common in males 
(1 in 54) than in females (1 in 252)2. The cause of the rise in numbers is currently unknown and, 
because the cause of autism has yet to be identified, these numbers will continue to increase. 
This problem is not only a cause for concern within the general public but also within the 
medical profession because there are many medical needs for a child with autism.  
 Sleep disturbances are reported in up to 89% of children with autism3. Some of the most 
common sleep dyssomnias reported in children with autism are difficulties falling asleep, 
recurrent night awakenings, and total length of time asleep. The occurrence of sleep disturbances 
put children with autism at greater risk for more complex complications like further 
developmental delays, behavioral difficulties, and psychological concerns3. These sleep 
disturbances can cause issues not only for the child but the caretaker as well. As physician 
assistants it is our duty to not only give guidance to parents with autistic children but also to 
better the lives of the children themselves. 
 Melatonin is an inexpensive and readily available, over the counter solution for not only 
autistic children with sleep disturbances but also for the general public with sleep difficulties. A 
bottle of 100 3mg tablets costs $5.99 in a drug store like GNC or CVS4. This cost is far less than 
any prescribed sleep aid such as Ambien CR, Lunesta, and Sonata that costs an average of $56, 
$56, and $38 respectively for only seven doses5. 
 Autism is a multisystem condition that has to be handled by a wide range of physicians. 
While a pediatrician can handle the child’s overall health and any acute problems that arise, 
psychologists and speech therapists should handle issues such as cognitive delay and speech. 
Physical therapists can be referred to for musculature and motor function complications. By 
improving the child’s sleep you therefore improve their growth, behavior issues, and 
psychological problems. It is therefore assumed that with better general overall health autistic 
patients would have less frequent office visits.  
 There are many different hypotheses about why children with ASD have sleep 
disturbances. One of the most recent theories involves the N-Acetylserotonin O-
methyltransferase (ASMT) gene that is responsible for encoding the last enzyme of melatonin 
synthesis. In children with ASD, this gene was shown to be significantly less active, thus 
indicating lower levels of melatonin6. 
 Current treatment for children that have ASD with associated sleep disturbances includes 
antiepileptic therapies such as carbamazepine, gabapentin, topiramate, and valproic acid; 
psychological therapies including behavioral management and one-on-one therapy sessions; and 
antidepressants like mirtazapine and trazodone7. 
 Melatonin has been used to treat insomnia associated with shift work, jet lag, and delayed 
sleep for decades3. It is thought that because there has been evidence that suggests children with 
ASD have a lower blood level of melatonin at night, synthetically substituting the melatonin will 
improve sleep. 
Objective 
 The objective of this selective EBM review is to determine whether or not melatonin is 
an effective treatment for sleep problems in autism. 
Methods 
 Patients in this study were between the ages of 2 and 16 years old with a diagnosed 
autism spectrum disorder that have significant sleep difficulties as reported by either their 
parents or physicians. One study reviewed is a double blind, randomized, placebo-controlled, 
crossover trial3. Another is a randomized, controlled, crossover trial6. Finally, the third study 
reviewed is a randomized controlled trial8. The intervention evaluated throughout the three trials 
was giving the participant a dose of melatonin between 2 and 10 mg before bedtime. In one of 
the studies the child was started on 2mg 30-40 minutes prior to bedtime and titrated every three 
nights by 2 mg to a max of 10 mg until “good sleep was achieved6. Another study allowed only 3 
mg of medication delivered 30 minutes prior to bedtime over a two-week trial3. Finally a study 
gave participants a 5 mg dose of medication for four weeks8. The comparison to the treatment 
group receiving melatonin was the experimental group who received a visually matched placebo. 
The outcomes analyzed all qualified as patient oriented evidence that matters (POEMs) and 
included total night’s sleep duration, number of awakenings, and sleep latency time.  
 The three studies reviewed were all written in English and published in peer-reviewed 
journals (Journal of Autism Development Disorder, Journal of Clinical Sleep Medicine, and The 
Authors Journal) in the years of 2006,2008, and 2010. The author using key words autism and 
melatonin performed a detailed search using research databases such as PubMed, Cochrane, and 
DynaMed. Table 1 illustrates the specific inclusion and exclusion criteria for each study. 
Inclusion criteria included children between the ages of 2 and 16 years old diagnosed with ASD 
by a pediatrician, psychologist, and WHO research diagnostic criteria without successful 
behavior management and free of medications. Exclusion criteria included children who had 
previously used melatonin as well as children currently on any sedative or psychotropic 
medication. One study allowed children to participate if there was a 4-week medication free 
period completed prior to the trial8. The summary of statistics reported and utilized in the studies 
were confidence intervals (CI), p-values, relative risk increase (RRI), absolute risk increase 
(ARI), and number needed to harm (NNH).  
Table 1: Demographics & Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Garstang 
(2006) 
Randomized 
placebo-
controlled 
double blind 
trial 
11 4-16 - Diagnosed 
with ASD by a 
pediatrician or 
psychologist 
- Children with 
learning 
disabilities, 
ADHD, and 
dyspraxia 
-Children that 
had used 
melatonin 
previously 
-Children 
who had been 
using other 
sedative 
medication 
not allowed 
trial entry 
until they had 
completed 4 
weeks of 
medication 
4 Regime of 
5mg of 
melatonin 
Wright 
(2010) 
Double blind 
randomized 
controlled 
crossover 
trial 
20 3-16 -Children with 
ASD who had 
been referred 
because of 
serious sleep 
problems 
-ASD 
diagnosed 
based on WHO 
research 
diagnostic 
criteria 
-Non successful 
-Children 
previously or 
currently on 
melatonin 
-On 
psychotropic 
medication 
-Those 
suffering 
from related 
disorders like 
Fragile X or 
Rett’s 
3 Started on 
2mg 
melatonin 
30-40 
minutes 
before 
bedtime and 
increased 
2mg every 
three nights 
to max dose 
of 10mg 
behavior 
management 
Wirojanan 
(2008) 
Randomized 
double blind, 
placebo-
controlled, 
crossover 
trial  
18 2-15.3 -ASD was 
diagnosed by a 
team of 
developmental 
pediatricians 
and 
psychologists 
-Free from 
medications 
None 6 Regimen of 
melatonin 
3mg, 30 
minutes 
before 
bedtime. 
 
Outcomes Measured 
 The outcomes measured in the reviewed studies are all Patient Oriented Evidence that 
Matters (POEMs). Wirojanan et al3 measured participants after a 1 week baseline period, 
children were then instructed to take a 2 week medication consisting of either placebo or 
melatonin 30 minutes prior to bedtime. Total night sleep duration, sleep-onset latency (the time 
from bedtime to sleep onset time), and number of night awakenings were recorded using a sleep 
diary, completed by the parent or guardian, and Actiwatch3. Actiwatch is a wrist-worn device 
that measures the activity counts each minute. A count of 100 or above for 2 consecutive minutes 
was considered the beginning of an awakening3. Differences between the melatonin group and 
placebo group were compared and analyzed via p-values. Wright et al6 measured a baseline for 
two groups for 1 month. Sleep diaries were kept by the parent or guardian and collected by the 
researcher every month for 9 months. These sleep diaries recorded sleep latency (time from 
starting bedtime routine to sleep), total sleep time, and number of awakenings. These values 
were again analyzed via p-values. A Side Effects Questionnaire (SEQ) was also kept by the 
parents recording all literature and manufacturer reported side effects for melatonin, theoretical 
side effects, common generic side effects and any other noted changes in health and wellbeing6. 
These results were analyzed and reported using p-value. Garstang et al8 measured a baseline 
assessment for 1 week before the medication was distributed. Once the medication was 
distributed a 4 week monitoring period went on where the parents used a sleep chart to record the 
total sleep time, sleep latency, and number of awakenings. This data was then analyzed using 
95% confidence intervals for the baseline period, placebo period, and melatonin period. 
Results 
 In the study performed by Wirojanan et al,3 18 patients (16 boys, 2 girls) ages 2 to 15.3 
years old were recruited through the Medical Investigation of Neurodevelopmental Disorders 
(M.I.N.D) Institute clinic at the University of California, Davis. The participants were given a 
number based on the order they were enrolled in the study. The document identifying the patient 
to their number was locked in the investigator’s file until the study concluded3. Patients 
conducted a 1-week baseline period and then randomized into treatment and placebo groups. The 
participants were told to administer 3mg oral medication 30 minutes prior to bedtime3. For all 
three studies, statistical analysis was done on the intent to treat (ITT) population. This study only 
included continuous data that could not be converted into dichotomous data.  
 Six participants were not included in the final results of the study. Three of the six were 
excluded because their caregiver failed to complete the sleep diaries. Another was excluded 
because their Actiwatch was not worn during the treatment block. One of the subjects was 
excluded because their Actiwatch was not worn during the intervention block. Finally, one other 
was excluded because the family did not follow the studies protocol3.  
 The total night’s sleep, sleep latency time, and number of night awakenings were 
recorded using both actigraph and a daily sleep diary. Actiwatch data consisted of activity counts 
for each 1-minute epoch3. This data was extracted from the watch and analyzed with ActiWare 
software. The criteria for a child to be considered awake was an activity count of 100 or above 
for two consecutive minutes3. All participants’ data was used in a complete case analysis (CC), 
in which only cases that completed all observations were included3. Parametric t-test was also 
used to compare the averages of all participants3. P-value was recorded and determined to be 
significant for both night sleep duration and sleep-latency time (see table 2)3. While number of 
night awakenings did not demonstrate a significant p-value table 3 demonstrates there was a 
decrease while on melatonin. 
Table 2: Nonparametric Analysis of the Sleep Variables for the CC Data Set 
Sleep variables Data se t  p Value   
Night sleep duration CC 0.0019 
Sleep-latency time CC 0.0001 
Number of night awakenings CC 0.93 
 
Table 3: Comparison of Sleep Variables During Placebo and Melatonin 
Variables Placebo  Melatonin p Value   
Total  night sleep 
duration, h:min 
7:54 (1:07) 8:15 (1:15) 0.057 
Sleep-latency time, 
min:s 
53:35 (60:33) 25:30 (16:53) 0.10 
Awakenings, 
no./night 
2.07 (1.5) 1.99 (1.2) 0.73 
 
 In the study performed by Wright et al6, 20 children  (16 male, 4 female) ranging from 
ages 4 to 16 years old were selected to participate in the study6. They were selected after being 
referred for serious sleep problems by their pediatrician or specialist CAMHS (child and 
adolescent mental health services). Children excluded were those previously or currently on 
melatonin, those currently on psychotropic medication, and those suffering from related 
developmental or neurological disorder, such as Fragile X or Rett syndrome6. Children also had 
to have had previous behavior management that had failed to be included.  
 Seventeen patients completed the study and were included in the final data6. One 
participant dropped out because it was too difficult to give medication, one because the guardian 
did not complete the diary, one because of significant benefits, and one because of apparent 
ineffectiveness of the medication6. These seventeen were randomized into treatment and placebo 
groups. A sleep diary was kept in order to record data for total sleep, sleep latency, and number 
of awakenings6. A side effects questionnaire (SEQ) to measure all literature and manufacturer 
reported side effects for melatonin, theoretical side effects, common generic side effects and any 
other noted changes in health or wellbeing was taken at the start of the study, end of the study, 
and after every 3 month period6.  
 After randomizing the 2 groups, everyone was monitored for 1 month to get a baseline. 
Then patients were placed on either placebo or melatonin for 3 months. Everyone started on 2 
mg 30-40 minutes before bedtime6. The parents increased the dose every three nights by 2mg 
maxing out at 10 mg6. If guardian noticed “good sleep” the child was stabilized at that current 
dosage6. For data in the SEQ, baseline scores were compared using Mann-Whitney U- Test6. For 
melatonin and placebo score comparison a Wilcoxon Signed Ranks Test was used6. All analyses 
were performed on SPSS and a p-value of <0.05 was considered to indicate statistical 
significance6. There was statistical significance in sleep latency and total sleep (table 4). 
However, there was no significance in number of night awakenings. Also, there was no 
significance reported for the SEQ. Stating all reported side effects had a p-value of greater than 
0.056. Specifically daytime drowsiness had a CER of 68.8% from the placebo and EER of 35.3% 
from the melatonin. The RRI was determined to be -48.7%. The ARI was calculated at -33.5% 
and the NNH were determined to be -2.9 (or 3 patients) see table 5. 
Table 4: Mean scores on sleep diary, general health questionnaire, and sleep difficulties 
questionnaire for baseline, melatonin and placebo arms of the trial 
Sleep diary Base line  Melatonin Placebo Mean 
difference  
Test statistic 
Sleep latency 
(min) 
135.0 (63.0) 82.84 (50.61) 124.79 46.7 (55) t(15)=3.394, p= 
0.004 
No. of 
awakenings 
0.5 (0.5) 0.43 (0.64) 0.58 (0.74) 0.1 (0.4) t(15)=1.313, p= 
0.209 
Total sleep 
[min] 
499.9 (66.4) 556.11 (53.59) 507.66 (70.67) 52.3 (55.1) t=3.75, p= 0.002 
 
Table 5: SEQ Calculations 
 
 In the study performed by Garstang et al8, 11 children (7 male, 4 female) ranging from 
ages 4 to 16 years old were selected to participate by recruitment from community pediatricians, 
special schools, local autism-support service and local parent-support groups8. Children who had 
used melatonin previously were excluded8. While children who had been using other sedative 
medication had to complete a 4-week medication free trial before allowed entry. 
 Seven children completed the study. The trial had to be suspended because of the placebo 
pill being empty. This suspension forced two girls to drop out8. One boy dropped out because of 
a housing relocation and one girl became involved in a child protection enquiry8. 
 Children were randomized into either the treatment or placebo group at the beginning of 
the study. A sleep diary taken by the guardian was used to measure total sleep, wakings per night 
and sleep latency. Their guardians were told to keep a 1-week sleep diary prior to the study 
beginning in order to establish a baseline8. The participants were then given 5mg of either 
melatonin or a look-a-like placebo and told to take orally before bedtime8. The guardians were 
advised to keep a sleep diary recording total sleep time, sleep latency and night awakenings for 4 
weeks. A 1-week washout was performed and then another 4-week trial was started8. The mean 
YOUR CALCULATIONS for Harm – 
using dichotomous data 
Daytime Drowsiness 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed to 
harm (NNH) 
CER 
 
Placebo 
EER 
 
Melatonin 
EER- CER 
CER 
35.3 – 68.8 
68.8 
EER – CER 
 
35.3 – 68.8 
1/ARI 
 
1/-33.5 
68.8% 35.3% - 48.7% - 33.5% - 3 (3 patients) 
and 95% Confidence interval (CI) were calculated and reported (see table 6). The study reported 
that all children completing the study remained on melatonin and that 75% of patients that 
dropped out were eventually prescribed melatonin8. 
Table 6: Mean and 95% confidence intervals (CI) of treatment on sleep patterns 
Sleep latency (h) Wakings per night Total sleep (h)  
Mean 95% CI Mean 95% CI Mean 95% CI 
Base line  2.60 2.28-2.93 0.35 0.18-0.53 8.05 7.65-8.44 
Placebo 1.91 1.78-2.03 0.26 0.20-0.34 8.75 8.56-8.98 
Melatonin 1.06 0.98-1.13 0.08 0.04-0.12 9.84 9.68-9.99 
 
Discussion 
 This systematic review investigated three studies to determine whether or not the use of 
melatonin in children with ASD was a viable option to treat and improve sleep patterns. All three 
studies demonstrated that the use of melatonin significantly improved total night sleep and sleep 
latency times when compared to the placebo.  
 While all three studies used different dosages of melatonin it is undetermined as to 
whether or not melatonin is a better treatment option when compared to other current 
pharmacological treatments like antiepileptic therapies or antidepressants. Wirojanan et al. 
conclude that the use of melatonin in combination with behavior therapies and proper sleep 
hygiene practices should be used for best effective results3.  
 Among the studies included in this selective review, there were several limitations 
expressed by each study. In both Wright et al. and Wirojanan et al. studies, the suggestion that 
bioavailability and metabolism may play a role into the effectiveness of being treated with a set 
dosage of melatonin was discussed. Wirojanan et al stating, “some participants may have needed 
higher dose for obtaining a significant response, whereas other might have benefited from lower 
dose.”3 While Wright et al. used a dosing range of 2mg to 10 mg and stating, “some children 
may require larger doses than those being suggested in literature, and that there may be 
considerable variability in dose needed.”6. Additionally, both Wright et al. and Garstang et al. 
reported small sample sizes and difficulty with recruiting. Garstang et al. suggested that in future 
studies a multi-centre approach should be used because many of the participants were excluded 
because melatonin was already being used in their child with ASD. 
Conclusion 
 Based on the information provided in these three studies, it has been concluded that 
Melatonin is an effective treatment for children that struggle with sleep problems compared to 
placebo at doses of 2mg to 10 mg.   However, there are several issues with these studies that 
would require further examination. One main concern is the amount of children enrolled in all 
three studies. All three consisted of small numbers of participants, which can skew what a full 
spectrum view of the average population with ASD would look like. Another issue is 
bioavailability. One study allowed participants a dose range of 2mg to 10 mg while the other two 
studies only allowed a 3mg dose and 5mg dose. Due to the different severity types of ASD it is 
not known whether children with a more severe form of ASD require a larger dose of melatonin 
versus the children with a less severe form of ASD. 
 Future studies in this area of concern should be conducted to discuss the exact dosage of 
melatonin needed to increase outcomes of better sleep. These studies would have to be longer in 
length due to different groups testing different dosages of melatonin. Also instead of a wristband 
to measure sleep activity a camera could be installed in the child’s room to visually record the 
number of night awakenings. Neurologists and Pulmonologists should also be consulted to 
further classify when a participant is termed “awake” versus other psychological abnormalities.  
 
 
References 
 
1. National Institute of Neurological Disorders and Stroke. Autism Fact Sheet. NIH. August 
21, 2013. Available at http://www.ninds.nih.gov/disorders/autism/detail_autism.htm 
Accessed 9/20/13 
 
2. Centers for Disease Control. Autism Spectrum Disorders (ASDs) Data & Statistics. CDC. 
June 27,2013. Available at http://www.cdc.gov/ncbddd/autism/data.html Accessed 
10/20/13. 
 
3. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems 
in children with autism, fragile X syndrome, or autism and fragile X syndrome. J CLIN 
SLEEP MED. 2009;5(2):145-150. 
http://ezproxy.pcom.edu:2048/login?url=http://search.ebscohost.com/login.aspx?direct=tr
ue&db=jlh&AN=2010499840&site=ehost-live&scope=site. 
 
4. GNC. Melatonin. GNC Live Well. 2013. Available at 
http://www.gnc.com/family/index.jsp?categoryId=2104814 Accessed: 9/20/13. 
 
5. Consumer Reports. Cost Comparison of Newer Sleeping Pills. ConsumerReports.org. 
2011. Available at http://www.consumerreports.org/health/best-buy-
drugs/insomnia_drugs.htm Accessed: 9/20/13. 
 
6. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism 
spectrum conditions and severe sleep problems not amenable to behaviour management 
strategies: A randomised controlled crossover trial. J Autism Dev Disord. 
2011;41(2):175-184. 
http://ezproxy.pcom.edu:2048/login?url=http://search.ebscohost.com/login.aspx?direct=tr
ue&db=jlh&AN=2010909146&site=ehost-live&scope=site. doi: 10.1007/s10803-010-
1036-5. 
 
7. Kyle P. Johnson, Beth A. Malow, Assessment and Pharmacologic Treatment of Sleep 
Disturbance in Autism, Child and Adolescent Psychiatric Clinics of North America, 
Volume 17, Issue 4, October 2008, Pages 773-785, ISSN 1056-4993, 
http://dx.doi.org/10.1016/j.chc.2008.06.006.(http://www.sciencedirect.com/science/articl
e/pii/S1056499308000424) 
 
8. Garstang	  JW.	  Randomized	  controlled	  trial	  of	  melatonin	  for	  children	  with	  autistic	  spectrum	  disorders	  and	  sleep	  problems.	  Child:	  Care,	  Health	  &	  Development.	  2006;32(5):585-­‐589.	  http://ezproxy.pcom.edu:2181/eds/detail?vid=2&sid=754b5ceb-
31dc-404f-b817-
7a049eb963f3%40sessionmgr4004&hid=4103&bdata=JnNpdGU9ZWRzLWxpdmUmc2
NvcGU9c2l0ZQ%3d%3d#db=aph&AN=21870161 
 
